US 12,290,506 B2
Compositions and formulations for use of a PK inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders
Emma Taylor, San Francisco, CA (US); Karl Beutner, Fairfield, CA (US); Christopher Phillips, Doylestown, PA (US); Mark De Souza, Berkeley, CA (US); Ravi Kumar Pandrapragada, Clarksburg, MD (US); Vanessa Alexandra Cofré Urrutia, Santiago (CL); Brendan Philip Brady, Guildford (GB); and Charles Rodney Greenaway Evans, Godalming (GB)
Assigned to DermBiont, Inc., Boston, MA (US)
Filed by DermBiont, Inc., Boston, MA (US)
Filed on Apr. 1, 2024, as Appl. No. 18/623,901.
Application 18/623,901 is a continuation of application No. PCT/US2023/023014, filed on May 19, 2023.
Claims priority of provisional application 63/489,697, filed on Mar. 10, 2023.
Claims priority of provisional application 63/399,946, filed on Aug. 22, 2022.
Claims priority of provisional application 63/344,422, filed on May 20, 2022.
Prior Publication US 2024/0293368 A1, Sep. 5, 2024
Int. Cl. A61K 31/407 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 47/08 (2006.01); A61K 47/10 (2017.01); A61K 47/38 (2006.01); A61P 17/00 (2006.01)
CPC A61K 31/407 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 47/08 (2013.01); A61K 47/10 (2013.01); A61K 47/38 (2013.01); A61P 17/00 (2018.01)] 21 Claims
 
1. A topical composition comprising:
ruboxistaurin or a salt thereof;
2-(2-ethoxyethoxy)ethanol;
polyethylene glycol (PEG);
propylene glycol;
glycerin;
hydroxypropyl cellulose; and
one or more antioxidants,
wherein (i) the 2-(2-ethoxyethoxy)ethanol is 40% to 50% of the topical composition by weight; (ii) the polyethylene glycol is 10% to 20% of the topical composition by weight; (iii) the propylene glycol is 8% to 30% of the topical composition by weight; and (iv) the ruboxistaurin or a salt thereof is 0.01% to 1% of the topical composition by weight; and
wherein average molecular weight of the polyethylene glycol is from 200 to 900 Daltons.